The Food and Drug Administration’s recent approval of new treatment options for patients suffering from conditions such as cancer, rheumatoid arthritis and ulcerative colitis is the latest recognition of a nascent prescription drug sector known as biosimilars. The FDA’s actions are critical for promoting a vibrant U.S. marketplace for biosimilars, which have the potential to reduce costs in our health care system and increase access to care for millions of patients.

SOURCE: http://thehill.com/opinion/healthcare/353498-biosimilar-drugs-offer-promise-for-us-health-care-system?hl=en&ned=us